EPIPHANY Index for PE in Cancer
EPIPHANY Index: decision tree that classifies incidental or symptomatic pulmonary embolism in patients with cancer into low, intermediate or high risk of serious complications within 15 days.
Score interpretation
Serious complications within 15 days 1.6 %; 15-day mortality 0.3 % (derivation cohort).
→ May be suitable for outpatient management or early discharge if there is no other reason for admission; arrange early oncology follow-up.
Serious complications within 15 days 9.4 %; 15-day mortality 6.1 % (derivation cohort).
→ Individualise the setting of care; reassess vital signs, bleeding risk and tumour status early.
Serious complications within 15 days 30.6 %; 15-day mortality 17.1 % (derivation cohort).
→ Hospital management with close monitoring; involve the oncology and PE / respiratory teams.
Interpretation bands for the EPIPHANY Index. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Enoxaparin (LMWH) · Anticoagulant
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
